cobas b 101 system offers HbA1c diagnosis and monitoring at the Point of Care
IMPROVING THE OUTCOMES FOR PATIENTS LIVING WITH DIABETES.
The cobas b 101 system includes tests for glycated haemoglobin (HbA1c), lipid panel and C-reactive protein (CRP) on the same device.
Benefits for your patients
Better patient compliance
- Compared with laboratory testing, POC HbA1c testing has been shown to significantly increase the proportion of patients achieving their diabetes glycaemic control.1
- The cobas b 101 system includes tests for glycated haemoglobin (HbA1c), lipid panel and C-reactive protein (CRP) on the same device.
Simple and easy sample collection
- Direct blood sample application onto disc from a finger prick, with no need for tubes or pipettes for sample collection or transfer. Test discs can be conveniently stored at room temperature (2-30°c).
Fast turnaround time
- HbA1c result in 5 minutes. On the spot results in just 3 simple steps. Dual testing from one finger prick sample allows for HbA1c test and lipid panel within 15-minute workflow cycle.
Benefits of cobas b 101 System
Easy and intuitive to use
Colour touch screen with a user friendly interface that has the same look and feel of other Roche Point of Care devices.
Compact and portable
Lightweight and portable. Weighs 2kg, with small footprint.
Improves workflow efficiency
Patient data storage with 5,000 patient results. 500 QC results and 50 Operator IDs.
Automatic calibration on each disc
Samples and discs are checked for integrity and all steps of the process are controlled. No service required.
cobas b 101 Products
Frequently Asked Questions
COBAS AND COBAS B are trademarks of Roche. ©2020 Roche Diagnostics
cobas b 101 video
1. Bubner, T.K., Laurence, C.O., Gialamas, A., Yelland, L.N., Ryan, P., Willson, K.J. et al. (2009). Effectiveness of point-of-care testing for therapeutic control of chronic conditions: results from the PoCT in General Practice Trial. Med JAust 1 90, 624–6262. 2. Roche cobas b 101 Test Package Inserts. 3. www.ifcc.org (accessed Feb 2013) 4. NIH; NCEP Third Report, The National Heart, Lung and Blood Institute. 5. NICE clinical guidance [CG101] (2014). Available at: www.nice.org.uk/guidance/CG101 6. Roche (2013). Multicenter evaluation of the cobas b 101 system for the measurement of HbA1c and lipid panel 7. Roche (2018). Multicenter evaluation of the cobas CRP Test on the cobas b 101 POC system 8. Roche 2009. Accutrend Plus evaluation folder: The simple way to screen for cardiovascular disease risk factors. 2009. 9. Nagel D et al. Investigations of ascorbic acid interference in urine test strips. Clin Lab. 2006. 52 (3-4): 149-153. 10. Dempfle, CE et al. on behalf of the CARDIM study group. Sensitivity and specificity of a quantitative PoCT Ddimer assay using heparinized whole blood, in patients with clinically suspected deep vein thrombosis. Tromb Haemost 2006. 95: 79-83. 11. Derhaschnig, U et al. Diagnostic efficiency of a point-of- care system for quantitative determination of troponin T and myoglobin in the coronary care unit. PoCT 2004. 3(4): 162-164. 12. Schäfer, M et al. on behalf of the CARPRO Multicentre Study Group. Diagnostic equivalence of an NT-proBNP point-of-care test to the laboratory method in patients with heart failure and in reference populations. Point of Care: The Journal of Near-Patient Testing and Technology June 2010 - Volume 9 - Issue 2 - pp 91-97 13. Bertsch, T et al. on behalf of the cobas h 232 evaluators. Multicentre evaluation of a new point-of-care system for the determination of cardiac and thromboembolic markers (in preparation). Journal of Clin Lab. 2010:56(1-2):37-49 14. Plesch W et al. Results of the performance verification of the CoaguChek XS system. Tromb Res 2008. 123: 381-389.